News You Should Know: 3 Takeaways from Top Managed Care Articles May

Although Aduhelm stumbled, Leqembi has received full FDA approval, and Eli Lilly has reported positive results for donanemab.

In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.

The approval of Mounjaro (tirzepatide) for weight loss could be a tipping point for weight-loss drugs.

Ocaliva and resmetirom may be approved by the FDA this year.

Sarepta Therapeutics and Roche are competing with Pfizer to develop the first gene replacement therapy for Duchenne muscular dystrophy. Sarepta and Roche are ahead after the FDA put a clinical hold on Pfizer’s product.

Three ADCs are in late-stage trials as treatments for patients with non-small cell lung cancer.